Clinical Trial Update: Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema [Phase 2]

View source ↗

Summary

This is a Phase 2 dose-ranging study of an ocular sirolimus formulation for diabetic macular edema that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Rapamycin (sirolimus) ocular formulation (sirolimus)

Snippet

Sponsor: Santen Inc. | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED